The April 1, 2016, article by Piccart-Gebhart et al entitled “Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial” (J Clin Oncol 34:1034-1042, 2016) was published with errors in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Baselga’s COIs were given as:

José Baselga

Consulting or Advisory Role: Novartis, Juno Therapeutics, Aura Biosciences, Verastem, Infinity Pharmaceuticals

They should have read as:

José Baselga

Leadership: Infinity Pharmaceuticals, Aura Biosciences

Stock or Other Ownership: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Aura Biosciences, Apogen, Seragon

Honoraria: PMV Pharma, Juno Therapeutics, Infinity Pharmaceuticals, GRAIL, Seragon

Consulting or Advisory Role: Novartis, Eli Lilly, GRAIL, AstraZeneca

Research Funding: Roche/Genentech

Travel, Accommodations, Expenses: Roche/Genentech

This has been corrected as of January 11, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02210>

The May 20, 2016 article by Hong et al entitled “Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer” (J Clin Oncol 34:1764-1771, 2016) was published online September 27, 2016, with errors of omission in the AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section.

Dr. Burris’ COIs were given as:

Howard Burris

No relationship to disclose

They should have read as:

Howard A. Burris

Employment: HCA Healthcare/Sarah Cannon

Leadership: HCA Healthcare/Sarah Cannon

Stock and Other Ownership Interests: HCA Healthcare/Sarah Cannon

Consulting or Advisory Role: Mersana Therapeutics (Inst), AstraZeneca (Inst), Janssen (Inst), Novartis (Inst), Roche/Genentech (Inst), TG Therapeutics (Inst), MedImmune (Inst), Bristol-Myers Squibb (Inst), Astellas (Inst), Baxter Healthcare (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), Bayer Healthcare (Inst), Merck (Inst), GlaxoSmithKline (Inst), Pfizer (Inst), Vertex (Inst), Gilead Sciences (Inst), Sanofi-Aventis (Inst), Chugai

(Inst), E.R. Squibb & Sons (Inst), Eisai (Inst), Grifols USA (Inst), Incyte (Inst), Medivation (Inst), Otsuka (Inst), Amgen (Inst), Ipsen (Inst), Prostrakan (Inst), Tolmar (Inst), Genzyme (Inst), Helsinn (Inst), Spectrum Pharmaceuticals (Inst)

Research Funding: Roche/Genentech (Inst), Bristol-Myers Squibb (Inst), Incyte (Inst), Mersana Therapeutics (Inst), AstraZeneca (Inst), MedImmune (Inst), MacroGenics (Inst), Novartis (Inst), Boehringer Ingelheim (Inst), Eli Lilly (Inst), Seattle Genetics (Inst), AbbVie (Inst), Bayer (Inst), Celldex Therapeutics (Inst), Merck (Inst), Celgene (Inst), Agios Pharmaceuticals (Inst), Jounce Therapeutics (Inst), GlaxoSmithKline (Inst), Verastem (Inst), Tesaro (Inst), Immunocore (Inst), Takeda (Inst), Millennium (Inst), BioMed Valley Discoveries (Inst), Pfizer (Inst), TG Therapeutics (Inst), Loxo (Inst), Vertex (Inst), eFFECTOR Therapeutics (Inst), Janssen (Inst), Gilead Sciences (Inst), Valent Technologies (Inst), H3 Biomedicine (Inst), OncoMed (Inst), Regeneron (Inst), Sanofi (Inst), Medivation (Inst), Mirna Therapeutics (Inst), Amgen (Inst), Ventana Medical Systems (Inst), Acerta Pharma (Inst), Exelixis (Inst), Array BioPharma (Inst), StemCentrx (Inst), BIND Therapeutics (Inst)

This has been corrected as of January 7, 2019. The author apologizes for the errors.

DOI: <https://doi.org/10.1200/JCO.18.02264>